XTANDI

• drugenzalutamide112 co-mentions · 28 sources
• tagApproval112 co-mentions · 28 sources
• tagSmall Molecule56 co-mentions · 28 sources

Trials studying XTANDI

• phase2Pan Tumor Rollover Studyrecruitingn=1,500
• phase3The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)recruitingn=520
• phase2A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCrecruitingn=123
• phase2Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.recruitingn=192
• phase2A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetaterecruitingn=126
• phase2An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)recruitingn=150
• phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)recruitingn=1,314
• phase2A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancerrecruitingn=212